Clinical

The AJMC^® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care^® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.

Latest News

COVID-19 3D rendering | Image Credit: Production Perig - stock.adobe.com

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

By Brooke McCormick

July 8th 2025

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

Paxlovid box | Image Credit: Mike Mareen - stock.adobe.com

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

By Brooke McCormick

July 8th 2025

AJMC

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

By Shirley Cohen-Mekelburg, MD, MS
Jeffrey Gibbs, MD

July 8th 2025

Atopic dermatitis | Image Credit: © slobodyan_78-stock.adobe.com

Rezpegaldesleukin Potentially Promising for Atopic Dermatitis

By Marie Bosslett

July 8th 2025

Cases Show How Epcoritamab Revived CAR T Cells After Relapse in DLBCL

Cases Show How Epcoritamab Revived CAR T Cells After Relapse in DLBCL

By Mary Caffrey

July 7th 2025

More News

Blood Test Can Identify Those at Risk of Developing TB, Study Finds

Blood Test Can Identify Those at Risk of Developing TB, Study Finds

A new blood test being developed in the United Kingdom has been shown to not only identify those infected with human tuberculosis (TB) but also identify those most at risk of developing it.

Read More

Lenalidomide Proves Effective in Treating Smoldering Multiple Myeloma

Lenalidomide Proves Effective in Treating Smoldering Multiple Myeloma

Sara Karlovitch

A new study by Mayo Clinic Researchers calls into question the current standard of care for treating smoldering multiple myeloma.

Read More

Multiple Sclerosis Remains Tricky to Identify, Diagnose

Multiple Sclerosis Remains Tricky to Identify, Diagnose

Sara Karlovitch

Two abstracts presented at the American Academy of Neurology 2019 Annual Meeting evaluated misdiagnosis of multiple sclerosis.

Read More

Final Thoughts on Approach to Multiple Myeloma Treatment

Final Thoughts on Approach to Multiple Myeloma Treatment

Watch

Biochemical Versus Symptomatic Relapse Treatment Choices in MM

Biochemical Versus Symptomatic Relapse Treatment Choices in MM

Watch

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Watch

Patient Cost Implications in Multiple Myeloma Treatment

Patient Cost Implications in Multiple Myeloma Treatment

Watch

$Treatment Options in Relapsed/Refractory Multiple Myeloma$

Treatment Options in Relapsed/Refractory Multiple Myeloma

Watch

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

Watch

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

Watch

The Impact of OCM in the Treatment of Multiple Myeloma

The Impact of OCM in the Treatment of Multiple Myeloma

Watch

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

Watch

MAIA Trial: Transplant-Ineligible Patients With MM

MAIA Trial: Transplant-Ineligible Patients With MM

Watch

Using MRD Negativity to Stop Maintenance Therapy in MM

Using MRD Negativity to Stop Maintenance Therapy in MM

Watch

Long-term Data on Improving OS for Patients With MM

Long-term Data on Improving OS for Patients With MM

Watch

Payer Perspective: Transplant and Toxicities in MM Therapy

Payer Perspective: Transplant and Toxicities in MM Therapy

Watch

FORTE Trial: Transplant in Patients with Multiple Myeloma

FORTE Trial: Transplant in Patients with Multiple Myeloma

Watch

Impact of Maintenance Therapy in Multiple Myeloma

Impact of Maintenance Therapy in Multiple Myeloma

Watch

Strategy for Up-front Therapy of Multiple Myeloma

Strategy for Up-front Therapy of Multiple Myeloma

Watch

Backbone Therapy in Newly Diagnosed Multiple Myeloma

Backbone Therapy in Newly Diagnosed Multiple Myeloma

Watch

How Real-World Data Can Address Problems in MM

How Real-World Data Can Address Problems in MM

Watch

$Dosing Strategies in Relapsed-Refractory MM$

Dosing Strategies in Relapsed-Refractory MM

Watch

$Initiating Treatment in Relapsed-Refractory MM$

Initiating Treatment in Relapsed-Refractory MM

Watch

What Is the Cost of Recurrence in Multiple Myeloma?

What Is the Cost of Recurrence in Multiple Myeloma?

Watch

Daratumumab in the Treatment Landscape for MM

Daratumumab in the Treatment Landscape for MM

Watch

Clinical Significance of MRD Testing in MM

Clinical Significance of MRD Testing in MM

Watch

Practical Implications of the MAIA Study for MM

Practical Implications of the MAIA Study for MM

Watch

Considerations for Transplant-Ineligible Patients

Considerations for Transplant-Ineligible Patients

Watch

NCCN Guidelines for Newly Diagnosed MM

NCCN Guidelines for Newly Diagnosed MM

Watch

Achieving the Best Outcomes for Patients With MM

Achieving the Best Outcomes for Patients With MM

Watch

...

194 195 196 197 198 199 200 201 202

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions